Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Article

Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases

Marie-Christine Brezak, Muriel Quaranta, Marie-Odile Contour-Galcera, Olivier Lavergne, Odile Mondesert, Pierrïck Auvray, Philip G. Kasprzyk, Gregoire P. Prevost and Bernard Ducommun
Marie-Christine Brezak
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Muriel Quaranta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Odile Contour-Galcera
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Lavergne
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Odile Mondesert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pierrïck Auvray
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip G. Kasprzyk
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregoire P. Prevost
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Ducommun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-05-0168 Published September 2005
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: September 2005 to April 2021

AbstractFull-text HTMLPDF
Total260431542291

Cited By

Article Information

Volume 4, Issue 9, pp. 1378-1387

DOI 
https://doi.org/10.1158/1535-7163.MCT-05-0168
PubMed 
16170030

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • July 15, 2005
  • May 23, 2005
  • June 25, 2005
  • Published first September 16, 2005.

Copyright & Usage 
American Association for Cancer Research

Author Information

  1. Marie-Christine Brezak1,
  2. Muriel Quaranta2,
  3. Marie-Odile Contour-Galcera1,
  4. Olivier Lavergne1,
  5. Odile Mondesert2,
  6. Pierrïck Auvray3,
  7. Philip G. Kasprzyk4,
  8. Gregoire P. Prevost1 and
  9. Bernard Ducommun2
  1. 1IPSEN, Institut Henri Beaufour, Les Ulis, France; 2Laboratoire de Biologie Cellulaire et Moléculaire du Contrôle de la Prolifération-Centre National de la Recherche Scientifique, UMR5088-IFR109 “Institut d'Exploration Fonctionnelle des Génomes,” Université Paul Sabatier, Toulouse, France; 3Cellis Pharma, Saint Malo, France; and 4IPSEN, Biomeasure, Milford, Massachusetts
  1. Requests for reprints: Bernard Ducommun, Laboratoire de Biologie Cellulaire et Moléculaire du Contrôle de la Prolifération-Centre National de la Recherche Scientifique, UMR5088, 118 route de Narbonne 4R3B1, 31062 Toulouse, France. Phone: 33-5-6155-8110; Fax: 33-5-6155-8109. E-mail: ducommun{at}cict.fr
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 4 (9)
September 2005
Volume 4, Issue 9
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases
Marie-Christine Brezak, Muriel Quaranta, Marie-Odile Contour-Galcera, Olivier Lavergne, Odile Mondesert, Pierrïck Auvray, Philip G. Kasprzyk, Gregoire P. Prevost and Bernard Ducommun
Mol Cancer Ther September 1 2005 (4) (9) 1378-1387; DOI: 10.1158/1535-7163.MCT-05-0168

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases
Marie-Christine Brezak, Muriel Quaranta, Marie-Odile Contour-Galcera, Olivier Lavergne, Odile Mondesert, Pierrïck Auvray, Philip G. Kasprzyk, Gregoire P. Prevost and Bernard Ducommun
Mol Cancer Ther September 1 2005 (4) (9) 1378-1387; DOI: 10.1158/1535-7163.MCT-05-0168
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
  • Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
  • Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells
Show more Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement